Joint Formulary & PAD

Beclometasone with formoterol and glycopyrronium (Trimbow NEXThaler) - Chronic Obstructive Pulmonary Disease (COPD)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Inhaler (dry powder)
Associated Icons :
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Beclometasone with formoterol and glycopyrronium (Trimbow NEXThaler)
Indication :
Chronic Obstructive Pulmonary Disease (COPD)
Group Name :
Triple therapy
Keywords :
LABA beta agonist, long acting, ICS, antimuscarinic, triple therapy
Brand Names Include :
Trimbow NEXThaler
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
2

Other Indications

Below are listed other indications that Beclometasone with formoterol and glycopyrronium (Trimbow NEXThaler) is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Chronic Obstructive Pulmonary Disease (COPD).

Committee Recommendations (1)

The Surrey Heartlands Area Prescribing Committee has agreed Trimbow® NEXThaler® as an option where triple therapy is indicated in the treatment of COPD. See COPD Guidelines for more information.

The locally preferred triple-therapy devices for COPD are:

Low carbon:
Trimbow NEXThaler (dry powder)
Trelegy Ellipta (dry powder)

Alternative devices:
Trimbow (pMDI). To be used with a spacer.

Prescribe devices by brand.